Latigo Biotherapeutics Reports Results for Quarter Ended June 30, 2026

What Happened
Latigo Biotherapeutics, Inc. filed a Form 8‑K on September 3, 2026 to announce its financial results for the quarter ended June 30, 2026. The company issued a press release on that date reporting its quarterly results; the press release is attached to the 8‑K as Exhibit 99.1. The filing was signed by Nima Farzan, President and Chief Executive Officer.

Key Details

• Filing date: September 3, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended June 30, 2026.
• Exhibit included: Exhibit 99.1 — press release dated September 3, 2026 (also referenced under Item 9.01).
• The 8‑K furnishes the press release; the filing text itself does not list the specific financial figures.

Why It Matters
This 8‑K indicates Latigo has publicly disclosed its latest quarterly results; investors should review the attached press release for details on earnings, revenue, cash position, guidance, or clinical/pipeline updates. Because the 8‑K furnishes the press release rather than embedding the numbers in the filing text, reading Exhibit 99.1 is necessary to evaluate the company’s recent financial performance and any material operational changes.